Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study -

Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study
Information type: Randomised controlled trials
Source: The Lancet Oncology
Specialities: Cancers
Summary
Interim analysis found no overall survival benefit for adjuvant bevacizumab compared to control in 1343 patients with resected melanoma at high risk of recurrence (HR 0•97; 95% CI 0•78—1•22; p=0•76). Longer follow-up is required to establish overall survival at 5 years.
UKMi comment
A related commentary discusses these interim findings and compares them with other systemic treatments for metastatic melanoma.
Related links: Comment